Real-World Multinational Survey of Chronic Inflammatory Demyelinating Polyneuropathy: Disease Characteristics and Therapeutic Landscape
Por:
Querol, L, Rinaldi, S, Borsi, A, Boggia, GM, de Courcy, J, Taylor, Y, Wright, J, Karmous, W, Noel, W, Gary, C, zu Hörste, GM
Publicada:
1 sep 2025
Resumen:
Background and Aims: Chronic inflammatory demyelinating polyneuropathy (CIDP) is an immune-mediated syndrome characterized by progressive muscle weakness and sensory impairment. Clinical similarities with other neuropathies can cause misdiagnoses and delayed diagnoses. Additionally, a large proportion of patients appropriately treated according to current guidelines still show residual disability. This real-world study aimed to characterize a global cohort of patients with CIDP. Methods: Data were drawn from the Adelphi CIDP Disease Specific Programme, a cross-sectional survey with retrospective data collection, conducted in China, France, Germany, Italy, Japan, Spain, the United Kingdom, and the United States between September 2022 and April 2023. Neurologists and neuromuscular specialists reported on patient demographic and clinical characteristics at the time of the survey. Patients self-reported treatment satisfaction, disease control, and health-related outcome measures. Results: Overall, 164 physicians provided data for 1056 patients, with 428 (40.5%) providing self-reported data. Patients were diagnosed with typical CIDP (69.2%) and variant CIDP (30.8%). Overall, initial misdiagnosis occurred in 37.2% of patients, with a median (interquartile range) diagnostic delay of 6.0 (3.0-12.0) months. Maintenance therapy was prescribed for 81.6% of patients, with corticosteroid use ranging from 25.7% in the United States to 80.0% in China. Some patients were dissatisfied by treatment outcomes (11.0%) and symptom control (12.2%). Overall, mean (SD) patient-reported scores were 62.1 (20.4) for I-RODS, 35.0 (11.1) for FACIT fatigue, and 0.662 (0.253) for EQ-5D-5L. Interpretation: Diagnostic delay and misdiagnoses were common occurrences across typical CIDP and variant CIDP. Despite the use of guideline treatments, there were unmet needs and a continued disease burden for patients.
Filiaciones:
Querol, L:
Hosp Santa Creu i St Pau, Barcelona, Spain
Rinaldi, S:
Univ Oxford, Nuffield Dept Clin Neurosci, Oxford, England
Borsi, A:
Johnson & Johnson Co, Janssen Cilag Ltd, High Wycombe, England
Boggia, GM:
Johnson & Johnson Co, Janssen Cilag SpA, Milan, Italy
de Courcy, J:
Adelphi Real World, Bollington, England
Taylor, Y:
Adelphi Real World, Bollington, England
Wright, J:
Adelphi Real World, Bollington, England
Karmous, W:
Johnson & Johnson Co, Janssen Cilag, Strasbourg, France
Noel, W:
Johnson & Johnson Co, Janssen Pharmaceut NV, Beerse, Belgium
Gary, C:
Johnson & Johnson Co, Janssen Cilag, Strasbourg, France
zu Hörste, GM:
Univ Hosp Munster, Munster, Germany
Green Submitted, hybrid
|